RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Oil Prices Drop as Middle East Supply Recovery Eases Market Concerns 
South Korea’s KOSPI Plunges as Apple Price Hikes and OpenAI IPO Delay Shake AI Chip Stocks 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
CDC Monitors 41 Americans After Andes Hantavirus Outbreak on Luxury Cruise Ship 
Asian Stocks Sink as Apple Price Hikes Spark AI Valuation Fears, South Korea and Japan Lead Selloff 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Gold Price Ends Lower for Fourth Week Despite Rebound as Fed Rate Hike Bets Strengthen 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Trump Administration Releases New UFO Files and Apollo Mission Records 
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028 
JW Pharmaceutical will use the zebrafish to develop new drugs and expand indications of its drug candidates.
To expedite the process, the South Korean drug developer has inked a memorandum of understanding (MOU) with Zefit, a domestic non-clinical trial institute that specializes in zebrafish models.
Zefit will provide disease-specific zebrafish models using gene editing technology and a drug screening platform.
Zebrafish, a tropical fish species whose genetic structure is more than 80 percent similar to humans, is increasingly being used as a non-clinical intermediary research model.
Zebrafish can replace mammalian experiments, according to Zefit.
Conducting experiments with zebrafish can bring down costs to about one-tenth of those for mammals.
JW Pharmaceutica plans to use zebrafish to bridge the gap between non-clinical and clinical research.
Zebrafish experiments can be 91 percent similar to those conducted with mammals.
According to Shin Jun-nyeong, CEO of Zefit, Interest in zebrafish is increasing among regulatory agencies such as the US Food and Drug Administration (FDA).
